MicroRNA‑146a regulates the transformation from liver fibrosis to cirrhosis in patients with hepatitis B via interleukin‑6

  • Authors:
    • Zhaohui Yang
    • Yulong Peng
    • Suxian Yang
  • View Affiliations

  • Published online on: April 16, 2019     https://doi.org/10.3892/etm.2019.7490
  • Pages: 4670-4676
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to measure the expression of microRNA (miR)‑146a in liver tissues, peripheral blood mononuclear cells (PMBC) and serum from patients with Hepatitis B and either liver fibrosis or cirrhosis, as well as to determine the regulatory mechanism of miR‑146a. A total of 36 patients with Hepatitis B and liver fibrosis and 25 patients with hepatitis B and liver cirrhosis admitted to Linyi People's Hospital (Shandong, China) between June 2012 and February 2016 were included in the present study. Reverse transcription‑quantitative polymerase chain reaction was performed to determine the expression of miR‑146a and interleukin (IL)‑6 mRNA in the liver tissue, PBMCs and serum. Western blotting was used to assess the expression of IL‑6 in liver tissues and PBMCs. An enzyme‑linked immunosorbent assay was conducted to measure IL‑6 levels in serum. To identify the direct interaction between IL‑6 and miR‑146a, a dual luciferase reporter assay was performed. IL‑6 mRNA expression in liver tissues, PBMCs and serum from patients with liver cirrhosis was significantly higher than that from patients with liver fibrosis (P<0.05). Furthermore, IL‑6 expression in liver tissues and PBMCs from patients with liver cirrhosis was enhanced and levels of IL‑6 protein in the serum of patients with liver cirrhosis were significantly elevated compared with patients with liver fibrosis (P<0.05). By contrast, levels of miR‑146a in liver tissues, PBMCs and serum from patients with liver cirrhosis were significantly downregulated (P<0.05) compared with patients with liver fibrosis. miR‑146a regulated the expression of IL‑6 by binding to its 3'‑untranslated region. Thus, in the transformation from liver fibrosis to cirrhosis, the upregulation of IL‑6 in liver tissues, PBMCs and serum may be associated with the downregulation of miR‑146a. miR‑146a directly targets IL‑6, which may regulate the occurrence and immune responses of Hepatitis B.

References

1 

Cabre A, Babio N, Lazaro I, Lázaro I, Bulló M, Garcia-Arellano A, Masana L and Salas-Salvadó J: FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study. Atherosclerosis. 222:229–234. 2012. View Article : Google Scholar : PubMed/NCBI

2 

Tawada A, Kanda T, Imazeki F and Yokosuka O: Prevention of Hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int. 10:574–593. 2016. View Article : Google Scholar : PubMed/NCBI

3 

de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodés J, et al: EASL international consensus conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 39 (Suppl 1):S3–S25. 2003.PubMed/NCBI

4 

Chen YC, Chu CM, Yeh CT and Liaw YF: Natural course following the onset of cirrhosis in patients with chronic Hepatitis B: A long-term follow-up study. Hepatol Int. 1:267–273. 2007. View Article : Google Scholar : PubMed/NCBI

5 

Chu CM and Liaw YF: Hepatitis B virus-related cirrhosis: Natural history and treatment. Semin Liver Dis. 26:142–152. 2006. View Article : Google Scholar : PubMed/NCBI

6 

Bataller R and Brenner DA: Liver fibrosis. J Clin Invest. 115:209–218. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Pinzani M: Liver fibrosis. Springer Semin Immunopathol. 21:475–490. 1999. View Article : Google Scholar : PubMed/NCBI

8 

Safadi R and Friedman SL: Hepatic fibrosis-role of hepatic stellate cell activation. MedGenMed. 4:272002.PubMed/NCBI

9 

Trepo C, Chan HL and Lok A: Hepatitis B virus infection. Lancet. 384:2053–2063. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Sun M and Kisseleva T: Reversibility of liver fibrosis. Clin Res Hepatol Gastroenterol. 39 (Suppl 1):S60–S63. 2015. View Article : Google Scholar : PubMed/NCBI

11 

Calvaruso V and Craxi A: Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int. 34 (Suppl 1):S85–S90. 2014. View Article : Google Scholar

12 

Jiang XI, Luo Y, Zhao S, Chen Q, Jiang C, Dai Y, Chen Y and Cao Z: Clinical significance and expression of microRNA in diabetic patients with erectile dysfunction. Exp Ther Med. 10:213–218. 2015. View Article : Google Scholar : PubMed/NCBI

13 

Jia W, Wu Y, Zhang Q, Gao GE, Zhang C and Xiang Y: Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring. Mol Clin Oncol. 3:851–858. 2015. View Article : Google Scholar : PubMed/NCBI

14 

Graziano A, Lo Monte G, Piva I, Caserta D, Karner M, Engl B and Marci R: Diagnostic findings in adenomyosis: A pictorial review on the major concerns. Eur Rev Med Pharmacol Sci. 19:1146–1154. 2015.PubMed/NCBI

15 

Hayes CN and Chayama K: MicroRNAs as biomarkers for liver disease and hepatocellular carcinoma. Int J Mol Sci. 17:2802016. View Article : Google Scholar : PubMed/NCBI

16 

Ichikawa Y, Joshita S, Umemura T, Shobugawa Y, Usami Y, Shibata S, Yamazaki T, Fujimori N, Komatsu M, Matsumoto A and Tanaka E: Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Hepatol Res. 47:226–233. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Liu Y, Cheng LS, Wu SD, Wang SQ, Li L, She WM, Li J, Wang JY and Jiang W: IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection. Clin Sci (Lond). 130:907–919. 2016. View Article : Google Scholar : PubMed/NCBI

18 

MacParland SA, Ma XZ, Chen L, Khattar R, Cherepanov V, Selzner M, Feld JJ, Selzner N and McGilvray ID: Lipopolysaccharide and tumor necrosis factor alpha inhibit interferon signaling in hepatocytes by increasing ubiquitin-like protease 18 (USP18) expression. J Virol. 90:5549–5560. 2016. View Article : Google Scholar : PubMed/NCBI

19 

Chang TS, Chen CL, Wu YC, Liu JJ, Kuo YC, Lee KF, Lin SY, Lin SE, Tung SY, Kuo LM, et al: Inflammation promotes expression of stemness-related properties in HBV-related hepatocellular carcinoma. PLoS One. 11:e01498972016. View Article : Google Scholar : PubMed/NCBI

20 

Li C, Deng M, Hu J, Li X, Chen L, Ju Y, Hao J and Meng S: Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels. Oncotarget. 7:17021–17034. 2016.PubMed/NCBI

21 

Chang L, Lan T, Wu L, Li C, Yuan Y and Liu Z: The association between three IL-6 polymorphisms and HBV-related liver diseases: A meta-analysis. Int J Clin Exp Med. 8:17036–17045. 2015.PubMed/NCBI

22 

Lan T, Chang L, Wu L and Yuan YF: IL-6 plays a crucial role in HBV infection. J Clin Transl Hepatol. 3:271–276. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Chinese Society of Hepatology, Chinese Medical Association: Chinese Society of Infectious Diseases, Chinese Medical Association, . The guidelines of prevention and treatment for chronic Hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 13:881–891. 2005.(In Chinese). PubMed/NCBI

24 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

25 

Badding MA, Schwegler-Berry D, Park JH, Fix NR, Cummings KJ and Leonard SS: Sintered indium-tin oxide particles induce pro-inflammatory responses in vitro, in part through inflammasome activation. PLoS One. 10:e01243682015. View Article : Google Scholar : PubMed/NCBI

26 

Hunter CA and Jones SA: IL-6 as a keystone cytokine in health and disease. Nat Immunol. 16:448–457. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Tanaka T, Narazaki M and Kishimoto T: IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 6:a0162952014. View Article : Google Scholar : PubMed/NCBI

28 

Baeuerle PA and Henkel T: Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 12:141–179. 1994. View Article : Google Scholar : PubMed/NCBI

29 

Tone M, Powell MJ, Tone Y, Thompson SA and Waldmann H: IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol. 165:286–291. 2000. View Article : Google Scholar : PubMed/NCBI

30 

Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M and Yao Y: Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 141:125–139. 2014. View Article : Google Scholar : PubMed/NCBI

31 

Luo Q, Ma X, Wahl SM, Bieker JJ, Crossley M and Montaner LJ: Activation and repression of interleukin-12 p40 transcription by erythroid Kruppel-like factor in macrophages. J Biol Chem. 279:18451–18456. 2004. View Article : Google Scholar : PubMed/NCBI

32 

Aarstad HH, Vintermyr OK, Ulvestad E, Kross K, Heimdal JH and Aarstad HJ: In vitro-stimulated IL-6 monocyte secretion and in vivo peripheral blood T lymphocyte activation uniquely predicted 15-year survival in patients with head and neck squamous cell carcinoma. PLoS One. 10:e01297242015. View Article : Google Scholar : PubMed/NCBI

33 

Varshney J and Subramanian S: MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics. Front Mol Biosci. 2:312015. View Article : Google Scholar : PubMed/NCBI

34 

Liz J and Esteller M: lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 1859:169–176. 2016. View Article : Google Scholar : PubMed/NCBI

35 

Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH and Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 10:R1012008. View Article : Google Scholar : PubMed/NCBI

36 

Abou-Zeid A, Saad M and Soliman E: MicroRNA 146a expression in rheumatoid arthritis: Association with tumor necrosis factor-alpha and disease activity. Genet Test Mol Biomarkers. 15:807–812. 2011. View Article : Google Scholar : PubMed/NCBI

37 

Yamasaki K, Nakasa T, Miyaki S, Yamasaki T, Yasunaga Y and Ochi M: Angiogenic microRNA-210 is present in cells surrounding osteonecrosis. J Orthop Res. 30:1263–1270. 2012. View Article : Google Scholar : PubMed/NCBI

38 

Li X, Gibson G, Kim JS, Kroin J, Xu S, van Wijnen AJ and Im HJ: MicroRNA-146a is linked to pain-related pathophysiology of osteoarthritis. Gene. 480:34–41. 2011. View Article : Google Scholar : PubMed/NCBI

39 

Li X, Kroin JS, Kc R, Gibson G, Chen D, Corbett GT, Pahan K, Fayyaz S, Kim JS, van Wijnen AJ, et al: Altered spinal microRNA-146a and the microRNA-183 cluster contribute to osteoarthritic pain in knee joints. J Bone Miner Res. 28:2512–2522. 2013. View Article : Google Scholar : PubMed/NCBI

40 

Curtale G, Citarella F, Carissimi C, Goldoni M, Carucci N, Fulci V, Franceschini D, Meloni F, Barnaba V and Macino G: An emerging player in the adaptive immune response: MicroRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. Blood. 115:265–273. 2010. View Article : Google Scholar : PubMed/NCBI

41 

Taganov KD, Boldin MP, Chang KJ and Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 103:12481–12486. 2006. View Article : Google Scholar : PubMed/NCBI

42 

Larner-Svensson HM, Williams AE, Tsitsiou E, Perry MM, Jiang X, Chung KF and Lindsay MA: Pharmacological studies of the mechanism and function of interleukin-1beta-induced miRNA-146a expression in primary human airway smooth muscle. Respir Res. 11:682010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yang, Z., Peng, Y., & Yang, S. (2019). MicroRNA‑146a regulates the transformation from liver fibrosis to cirrhosis in patients with hepatitis B via interleukin‑6. Experimental and Therapeutic Medicine, 17, 4670-4676. https://doi.org/10.3892/etm.2019.7490
MLA
Yang, Z., Peng, Y., Yang, S."MicroRNA‑146a regulates the transformation from liver fibrosis to cirrhosis in patients with hepatitis B via interleukin‑6". Experimental and Therapeutic Medicine 17.6 (2019): 4670-4676.
Chicago
Yang, Z., Peng, Y., Yang, S."MicroRNA‑146a regulates the transformation from liver fibrosis to cirrhosis in patients with hepatitis B via interleukin‑6". Experimental and Therapeutic Medicine 17, no. 6 (2019): 4670-4676. https://doi.org/10.3892/etm.2019.7490